Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/50—Pyridazines; Hydrogenated pyridazines
  • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• This invention relates to the administration of an mTOR inhibitor to a patient in need thereof, especially to a cancer patient.
• mTOR inhibitors are currently under evaluation as single agents or in various combinations for the treatment of a variety of cancers.
• Those mTOR inhibitors include the rapamycin analogs, AP23573 (ARIAD Pharmaceuticals, Inc.), everolimus (Novartis) and temsiralimus (Wyeth).
• Other mTOR inhibitors include, among others, sirolimus (rapamycin), and the additional analogs, ABT-578 and biolimus. While AP23573, everolimus and temsirolimus have all yielded positive results in human studies, mouth sores have been noted as a dose limiting toxicity.
• This invention provides a new approach for the administration of an mTOR inhibitor, especially to cancer patients.
• mTOR inhibitors are a recently expanded ciass of drugs useful for treating various cancers and other disorders. These include rapamycin (serolimus), AP23573, CCI779 (temserolimus), RAD001 (everolimus), which are mentioned above, as well as others. These drugs are typically administered in various dosages and on various schedules as tablets or as intravenous infusions. [0008] It has now been found, however, that conventional, simple dosing schedules can be suboptimal for mTOR inhibitors. More particularly, therapeutic doses of an mTOR inhibitor
• Page I of 18 administered daily, e.g., orally, typically for the treatment of any of a variety of cancers, is associated with the development of mouth sores in a subset of patients so treated, and of more severe mouth sores in a subset of those patients.
• decreasing the daily dose or adopting a less frequent dosing schedule risks a loss in effectiveness of the mTOR inhibitor regimen.
• a continuous (i.e., week after week) 4-day or 5-day per week dosing schedule e.g., QDx4 or QDx5 dosing
• This can permit larger daily doses of an mTOR inhibitor and greater cumulative exposure to the drug than would be preferred on a 7-day/week schedule — without unduly increasing the risk of mouth sores, especially the risk of more severe grades of such mouth sores.
• QDx4 and QDx5 dosing means that the mTOR inhibitor is administered to the patient in one or more doses per day for four or five consecutive days, respectively, followed by three or two days, respectively, without treatment with the mTOR inhibitor.
• the drug may be administered in one or more portions per day, e.g., twice a day ("bid") dosing.
• the administration of drug is maintained countinuously on a weekly basis, i.e., for at least two, and usually more than two, consecutive weeks (and thus without an intervening week without mTOR inhibitor).
• the mTOR inhibitor may be any mTOR inhibitor, although AP23573, temserolimus and everolimus are currently of particular interest.
• a typical daily dose is from 2mg to 80 mg of drug, e.g., 5 - 60 mg, or 10 - 50 mg, or 10 - 40 mg, or 10 - 30 mg.
• Oral administration of the drug e.g., in tablet or capsule form, is of particular interest.
• the QDx4 or QDx5 administration of this invention may further be supplemented with a loading dose of 2 - 300mg of an mTOR inhibitor given orally or parenterally on an intermittent basis, e.g., once per week, or once every second or third week.
• the mTOR inhibitor of the loading dose will usually be the same mTOR inhibitor given on the other days, but may be a different mTOR inhibitor.
• a loading dose which doubles or triples the normal daily dose is of particular current interest, as is administering the loading dose on the first day of the QDx4 or QDx5 cycle.
• the optional loading dose may be an additional 20 or 40 mg of the mTOR inhibitor on day 1 of each week, or on day 1 every other week, or on day 1 of every third week, by way of example.
• the mTOR inhibitor may be AP23573, everolimus, rapamycin or another mTOR inhibitor. That loading dose may be administered orally or may be given parenterally, e.g., by i.v. infusion, and may be coordinated, in cases of combination therapies, with the administration of the other anticancer drug(s) of the combination.
• the mTOR inhibitor may be administered as a monotherapy, or may be administered in coordination with the administration of one or more other drugs for treating the cancer or for alleviating the effects of the cancer or of any of the drugs given to the patient.
• dosages of each of the components of the combination are administered during a desired treatment period.
• the components of the combination may administered at the same time; either as a unitary dosage form containing both components, or as separate dosage units; the components of the combination can also be administered at different times during a treatment period, or one may be administered as a pretreatment for the other.
• the mTOR inhibitor may be administered by any pharmaceutically acceptable route, a variety of which are known for that class of drugs. Parenteral and, especially, oral administration are currently of particular interest.
• the mTOR inhibitors of greatest current interest are rapamycin analogs in which the hydroxyl group at position 43 is replaced, especially those analogs currently in clinical development for treating cancer, such as AP23573, Everolimus and Temsirolimus. These and other mTOR inhibitors are discussed in greater detail below.
• the mTOR inhibitor therapy disclosed herein should be of interest for a correspondingly wide range of cancers. Those include among others prostate, endometrial, breast, ovarian, cervical, head and neck, small cell and non-smal!
• sarcomas including the various bone and soft tissue sarcomas
• melanomas including the various bone and soft tissue sarcomas
• multiple myeloma B-cell lymphoma
• mantle cell lymphoma mantle cell lymphoma
• Non-Hodgkin's Lymphoma CLL and CML, including, among others, cases which are advanced, recurrent, refractory to one or more other therapies and/or metastatic.
• the therapy disclosed herein constitutes a new method for treating various types of cancer and other diseases, with the objective of providing a desirable therapeutic window for achieving clinical benefit without incurring an unacceptable level of side effects.
• the term “treating” refers to the administration of an mTOR inhibitor and a second drug to a patient after the onset, or suspected onset, of a cancer. “Treating” includes the concepts of "alleviating”, which refers to lessening the frequency of occurrence or recurrence, or the severity, of any symptoms or other ill effects related to a cancer and/or the side effects associated with cancer therapy.
• treating also encompasses the concept of "managing” which refers to reducing the severity of a particular disease or disorder in a patient or delaying its recurrence, e.g., lengthening the period of remission in a patient who had suffered from the disease.
• effective amount or “effective dose”, as used herein means the amount or dose of a substance that elicits a desirable biological or clinical response in a tissue or patient.
• a desirable response may include one or more of the following: delaying or preventing the onset of a medical condition, disease or disorder; slowing down or stopping the progression, aggravation or worsening of the condition or symptoms of the condition; ameliorating the symptoms of the condition; and curing the condition — e.g., where the condition, disease, disorder or symptoms associated with cancer or to side effects of anti cancer therapy.
• compositions and methods of the present invention can comprise additional or optional ingredients, components, or limitations described herein or otherwise useful in compositions and methods of the general type as described herein.
• Rapamycin is a macrolide produced by Streptomyces hygroscopicus and discovered in the 1970's. Rapamycin is a potent immunosuppressive agent and is used clinically to prevent rejection of transplanted organs. It has also been reported to have a wide range of interesting pharmacologic activities, making it and its derivatives of interest for a range of indications including the treatment and prevention of organ transplant rejection and autoimmune diseases, fungal infection, multiple sclerosis; rheumatoid arthritis, systemic lupus erythematosus [see e.g., U.S. Pat. No. 5.078.9991. pulmonary inflammation [U.S. Pat. No. 5,080.8991.
• insulin dependent diabetes mellitus U.S. Pat. No. 5.321.0091. skin disorders, such as psoriasis [U.S. Pat. No. 5.286,7301, bowel disorders [U.S. Pat. No. 5.286,7311, smooth muscle cell proliferation and intimal thickening following vascular injury [U.S. Pat. Nos. 5.288.711 and 5.516.7811. adult T-cell leukemia/lymphoma [European Patent Application 525,960 A1], ocular inflammation [U.S. Pat. No. 5,387.5891, malignant carcinomas [U.S. Pat. No. 5.206,0181. cardiac inflammatory disease [U.S. Pat. No. 5,496.8321.
• skin disorders such as psoriasis [U.S. Pat. No. 5.286,7301, bowel disorders [U.S. Pat. No. 5.286,7311, smooth muscle cell proliferation and intimal thickening following vascular injury [U.S
• rapamycin a number of derivatives of rapamycin, including AP23573 (ARIAD), CCI779 ("temsirolimus", Wyeth) and RAD001 ("Everolimus", Novartis) have yielded promising results in human studies against a variety of cancers.
• rapamycin and everolimus are used as immunosuppressants in organ transplant recipients. Rapamycin and a number of the C-43-modified rapamycin analogs, including among others AP23573, Biolimus and ABT-578 (Abbott), are being used, evaluated or developed for use on drug-eluting stents.
• mTOR inhibitors of interest include 42-desmethoxy derivatives of rapamycin and its various analogs, as disclosed, e.g., in WO 2006/095185 (in which such compounds are referred to as "39-desmethoxy" compounds based on their numbering system).
• the derivatives of rapamycin are of particular current interest in practicing this invention.
• a variety of oral and parenteral dosage forms are known for rapamycin and a number of rapamycin analogs. Some are currently in use in various treatment methods, monotherapies or otherwise. Those same dosage forms may likewise be used in the practice of the mTOR inhibitor therapy disclosed herein.
• Solid dosage forms are often preferred for oral administration and include among others conventional admixtures, solid dispersions and nanoparticles, typically in tablet, capsule, caplet, gel cap or other solid or partially solid form. Such formulations may optionally contain an enteric coating. Numerous materials and methods for such oral formulations are well known.
• the mTOR inhibitor is provided as an oral dosage form, such as a tablet.
• the drug may prepared by a wet granulation process.
• the tablet may contain one or more cellulose polymers and one or more of an antioxidant, chelating agent, filler, binder, surfactant, desintegrant, lubricant, pH-modifying agent and the like.
• the wet granulation process may be performed with an aqueous or alcoholic, e.g., ethanolic solvent system. Other suitable alcohols include methanol, isopropanol, and the like.
• the solvent can also be a mixture of solvents, e.g. an alcoholic solvent and water.
• composition contain from 1 to 45%, from 2 to
• Acceptable antioxidants include, but are not limited to, citric acid, d,l- ⁇ -tocopherol, BHA, BHT, monothioglycerol, ascorbic acid, and propyl gallate. It is expected that the antioxidants of the formulations of this invention will be used in concentrations ranging from 0.001 % to 3% wt/wt.
• Chelating agents, and other materials capable of binding metal ions such as ethylene diamine tetra acetic acid (EDTA) and its salts are capable of enhancing the stability of AP23573.
• EDTA ethylene diamine tetra acetic acid
• Typical cellulose polymers include, but are not limited to hydroxypropylmethylcellulose (HPMC), hydroxypropylmethyl cellulose phthalate, methyl cellulose (MC), hydroxyethyl cellulose, and hydroxypropyl cellulose (HPC).
• Acceptable pH modifying agents include, but are not limited to citric acid, sodium citrate, dilute HCI, and other mild acids or bases capable of buffering a solution containing AP23573 to a pH in the range of about 4 to about 6. If present in the composition, the pH modifying agent is usually in amount of up to 1%.
• Surfactants may be present in the formulation and include polysorbate 80, sodium lauryl sulfate, sodium dodecyl sulfate, salts of bile acids (taurocholate, glycocholate, cholate, deoxycholate, etc.) which may be combined with lecithin.
• ethoxylated vegetable oils such as Cremophor EL, vitamin E tocopherol propylene glycol succinate (Vitamin E TGPS), polyoxyethylene- polyoxypropylene block copolymers, and poloxamers.
• the surfactant is usually in amount of up to 20%, for example 1 to 15% by weight.
• Binders, fillers, and disintegrants such as sucrose, lactose, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, gum acacia, cholesterol, tragacanth, stearic acid, gelatin, casein, lecithin (phosphatides), carboxymethylcellulose calcium, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethyl- cellulose phthalate, noncrystalline cellulose, polyvinylpyrrolidone, cetostearyl alcohol, cetyl alcohol, cetyl esters wax, dextrates, dextrin, cyclodextrin, lactose, dextrose, glyceryl monooleate, glyceryl monostearate, glyceryl palmitostearate, polyoxyethylene alkyl ethers, polyethylene glycols, polyoxyethylene castor oil derivatives, polyoxyethylene stearates, and polyvinyl alcohol
• Any given formulation of this invention may contain multiple ingredients of each class of component.
• a formulation containing an antioxidant may contain one or more antioxidants as the antioxidant component.
• the tablet may further comprise a film-coat to control the release of the rapamycin analog.
• the tablet may be coated with a film-coat by spraying, dipping or by deposition.
• the film- coat typically includes a polymeric film-forming material such as copovidone (i.e a copolymer of polyvinylpyrrolidone and vinyl acetate), hydroxypropyl methylcellulose, hydroxypropylcellulose, and acrylate or methacrylate copolymers.
• the film-coat may further comprise a plasticizer, e.g. polyethylene glycol, triethyl citrate, a surfactant, e.g.
• the film-coating may also comprise talc as anti-adhesive.
• the film coat usually accounts for less than about 5% by weight of the dosage form.
• the film-coating material comprises copovidone.
• the film coating may also be an enteric layer comprising an enteric polymer, for delayed release of the rapamycin analog.
• An enteric layer is a coating of a substance (i.e a polymer) which is insoluble in the acid medium of the stomach but which is soluble at the higher pH encountered in the intestine. Such materials are used as film coatings on tablets to modify the release of a drug.
• Suitable enteric polymers are well known to those of skill in the art (WO 01/051031) and include, without limitation, methyl metacrylate polymers, methacrylic acid co-polymers, cellulose acetate phthalate, polyvinyacetate phthalate, hydroxypropyl methyl phthalate, and hydroxypropyl methyl cellulose phthalate.
• the enteric layer may comprise a methacrylic acid co-polymer such as Eudragit L100, Acryl-EZE or the like.
• the mTOR inhibitor therapy disclosed herein encompasses methods of treating, preventing and/or managing various types of cancer while providing a desirable therapeutic window for achieving clinical benefit without incurring an unacceptable level of side effects.
• Examples of cancers and cancer conditions that can be treated with the mTOR inhibitor therapy of this document include, but are not limited to, solid tumors such as sarcomas and carcinomas, lymphatic cancers and especially PTEN-deficient tumors (see e.g.
• PTEN-deficient tumors may be identified, using genotype analysis and/or in vitro culture and study of biopsied tumor samples.
• Non-limiting examples of cancers involving abnormalities in the phosphatidyl-inositol 3 kinase/Akt-mTOR pathway include, but are not limited to, glioma, lymphoma and tumors of the lung, bladder, ovary, endometrium, prostate or cervix which are associated with abnormal growth factor receptors (e.g., EGFR, PDGFR, IGF-R and IL-2); ovarian tumors which are associated with abnormalities in P13 kinase; melanoma and tumors of the breast, prostate or endometrium which are associated with abnormalities in PTEN; breast, gastric, ovarian, pancreatic, and prostate cancers associated with abnormalities with Akt; lymphoma, cancers of the breast or bladder and head and neck carcinoma associated with abnormalities in elF-4E; mantle cell lymphoma, breast cancer and head and neck carcinomas associated with abnormalities in Cyclin D; and familial melanoma and pancreas carcinomas
• solid tumors are meant tumors and/or metastasis, such as brain and other nervous system tumors (e.g. tumors of the meninges, brain such as glioblastoma and astrocytomas, spinal cord and other parts of the central nervous system); head and/or neck cancer; breast tumors; excretory system tumors (e.g. kidney, renal, pelvis, bladder and other unspecified organs); gastrointestinal tract tumors (e.g.
• brain and other nervous system tumors e.g. tumors of the meninges, brain such as glioblastoma and astrocytomas, spinal cord and other parts of the central nervous system
• head and/or neck cancer breast tumors
• excretory system tumors e.g. kidney, renal, pelvis, bladder and other unspecified organs
• gastrointestinal tract tumors e.g.
• oesophagus stomach, colon, small intestine, rectum, tumors involving the liver, gall bladder, pancreas and other parts of the digestive organs); oral cavity (lips, tongue, throat, mouth, tonsil, oropharynx, nasopharynx, and other sites); reproductive system tumors (e.g. vulva, cervix, uterus, ovary and other sites associated with female genitaf organs, penis, prostate, testis and other sites associated with male genital organs); respiratory tract tumors (e.g. nasal cavity, middle ear, sinuses, bronchus, lung and other sites); skeletal system tumors (e.g. bones, cartilage and other sites); skin tumors (e.g.
• malignant melanoma of the skin non-melanoma skin cancer, carcinoma, sarcoma
• tumors involving other tissues including peripheral nerves, connective and soft tissue, eye and adnexa, thyroid, adrenal gland and other endocrine glands and related structures, secondary and unspecified malignant neoplasm of lymph nodes, secondary malignant neoplasm of respiratory and digestive systems and secondary malignant neoplasm of other sites.
• lymphatic cancers are meant e.g.
• tumors of the blood and lymphatic system multiple myeloma, lymphoid leukemia, myeloid leukemia, acute or chronic lymphocytic leukemia, monocytic leukemia, other leukemias of specified cell type, leukemia of unspecified cell type, other unspecified malignant neoplasms of lymphoid, haematopoietic and related tissues, for example T-cell lymphoma or cutaneous lymphoma).
• Cancers that can be treated using this mTOR inhibitor therapy include among others cases which are refractory to treatment with other chemotherapeutics.
• refractory refers to a cancer (and/or metastases thereof), which shows no or only weak anti-proliferative response (e.g., no or only weak inhibition of tumor growth) after treatment with another chemotherapeutic agent. These are cancers that cannot be treated satisfactorily with other chemotherapeutics. Refractory cancers encompass not only (i) cancers where one or more chemotherapeutics have already failed during treatment of a patient, but also (ii) cancers that can be shown to be refractory by other means, e.g., biopsy and culture in the presence of chemotherapeutics.
• the mTOR inhibitor therapy described herein is also applicable to the treatment of patients who have not been previously treated.
• the mTOR inhibitor may be administered as described herein for treating, preventing and/or managing various types of cancers.
• the exact amount required will also vary from subject to subject, depending on age, and general condition of the subject, the severity of the cancer, the particular mTOR inhibitor, its mode of administration, and the like.
• the specific effective dose level of mTOR inhibitor for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts.
• Everolimus or Temsirolimus is administered to the patient every day for four to five consecutive days, followed by two or three days, respectively without treatment with the mTOR inhibitor.
• Everolimus or Temsirolimus is administered to the patient, twice a day, every day for four to five consecutive days, followed by two or three days, respectively without treatment with the mTOR inhibitor.
• Treatment using an mTOR inhibitor in accordance with this invention may be provided in combination with one or more other cancer therapies, include surgery, radiotherapy (e.g., gamma- radiation, neutron beam radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, and systemic radioactive isotopes, etc.), endocrine therapy, biologic response modifiers (e.g., interferons, interleukins, and tumor necrosis factor (TNF) to name a few), hyperthermia, cryotherapy, agents to attenuate any adverse effects (e.g., antiemetics), and other cancer chemotherapeutic drugs.
• the other agent(s) may be administered before, during or after administration of an mTOR inhibitor as provided by this invention and may be administered using a formulation, route of administration and dosing schedule the same or different from that provided herein for the mTOR inhibitor.
• compositions of the present invention can be employed together with other agents to attenuate any adverse effects (e.g., statins, pain medication, antiemetics, G-CSF, GM-CSF, etc.), and/or with other approved chemotherapeutic drugs.
• adverse effects e.g., statins, pain medication, antiemetics, G-CSF, GM-CSF, etc.
• other agents e.g., statins, pain medication, antiemetics, G-CSF, GM-CSF, etc.
• Such other drugs include but not limited to one or more of the following: an anti-cancer alkylating or intercalating agent (e.g., mechlorethamine, chlorambucil, Cyclophosphamide, Melphalan, and lfosfamide); antimetabolite (e.g., Methotrexate); purine antagonist or pyrimidine antagonist (e.g., 6- Mercaptopurine, 5-Fluorouracil, Cytarabile, capecitabine and Gemcitabine); spindle poison (e.g., Vinblastine, Vincristine, Vinorelbine and Paclitaxel); podophyllotoxin (e.g., Etoposide, Irinotecan, Topotecan); antibiotic (e.g., Doxorubicin, Bleomycin and Mitomycin); nitrosourea (e.g., Carmustine, Lomustine); inorganic ion (e.g., Cisplatin, Carboplatin, Ox
• Asparaginase hormone
• proteasome inhibitor such as Velcade, another proteasome inhibitor (see e.g., WO 02/096933) or another NF-kB inhibitor, including, e.g., an IkK inhibitor
• other kinase inhibitors e.g., an inhibitor of Src, BRC/Abl, kdr, f1t3, aurora-2, glycogen synthase kinase 3 ("GSK-3"), EGF-R kinase (e.g., Iressa, Tarceva, etc.), VEGF-R kinase, PDGF-R kinase, etc); an antibody, soluble receptor or other receptor antagonist against a receptor or hormone implicated in a cancer (including receptors such as EGFR, ErbB2, VEGFR, PDGFR, and IGF-R; and agents such as Herceptin (or other kinase inhibitors (or other kinase inhibitors).
• Src
• Examples of other therapeutic agents include among others, Zyloprim, alemtuzumab, altretamine, amifostine, nastrozole, antibodies against prostate-specific membrane antigen (such as MLN-591 , MLN591 RL and MLN2704), arsenic trioxide, bexarotene, bleomycin, busulfan, capecitabine, Gliadel Wafer, celecoxib, chlorambucil, cisplatin- epinephrine gel, cladribine, cytarabine liposomal, daunorubicin liposomal, daunorubicin, daunomycin, dexrazoxane, docetaxel, doxorubicin, Elliott's B Solution, epirubicin, estramustine, etoposide phosphate, etoposide, exemestane, fludarabine, 5-FU, fulvestrant, gemcitabine, gemtuzumab-
• the mTOR inhibitor therapy of this invention can also be employed together with one or more combinations of cytotoxic agents as part of a treatment regimen, wherein the combination of cytotoxic agents is selected from: CHOPP (cyclophosphamide, doxorubicin, vincristine, prednisone, and procarbazine); CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone); COP (cyclophosphamide, vincristine, and prednisone); CAP-BOP (cyclophosphamide, doxorubicin, procarbazine, bleomycin, vincristine, and prednisone); m-BACOD (methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethaso ⁇ e, and leucovorin); ProMAC E-MOPP (prednisone, methotrexate, methot
• Page I I of 18 variations including design choices in selecting, preparing, formulating and administering the mTOR inhibitor or the second drug of this invention, etc. are intended to be encompassed by the scope of the invention and of the appended claims.
• compositions of this invention may be prepared by any known or otherwise effective technique, suitable for making and formulating pharmaceutical dosage forms. Many such methods are described in the pharmaceutical arts or are otherwise well known to those skilled in their respective formulation arts.
• Croscarmellose Sodium were mixed in a high shear granulator.
• the AP23573 and Butylated Hydroxytoluene (BHT) were dissolved in Dehydrated Alcohol, USP, mixing not less than 45 minutes.
• the solution of AP23573 and BHT was added to the granulator and mixed to a wet mass for approximately 3 minutes.
• the milled, granulated material was pressed into tablets using a tablet press set up with 6 mm round concave tooling.
• the press was adjusted as required for a target tablet weight of 125.0 mg, hardness of 5.5 kp, friability no more than 1%, and disintegration time less than 10 minutes.
• a film coating may be prepared according to following procedure using the following components.
• the tablets are added to a coating pan and are coated with a solution of Copovidone in Dehydrated Alcohol, USP (20:80 w/w), maintaining a product temperature of 20-35 0 C, until a weight gain of 5% is achieved.
• the pan is then cooled and the film-coated tablets allowed to dry.
• Film- coated tablets may be packaged as such, or may be enteric coated.
• An enteric coating may be prepared according to following procedure using the following components.
• the tablets are placed in a coating pan and coated with a suspension of Methacrylic Acid Copolymer, NF, Triethyl Citrate, NF, and Talc in Dehydrated Alcohol, USP, maintaining a product temperature of 20-35 0 C, until a weight gain of 8% is achieved.
• the pan is then cooled, and the enteric-coated tablets allowed to dry.
• Eligible patients in cohorts of at least 3 patients initially are randomized at the same flat, fixed starting dose of 20 mg/day into one of three 28-day dosing schedules, i.e. once daily continuous dosing for 4 days every week (QDx4), 21 of 28 days (QDx21), or all 28 days (QDx28).
• the subsequent dose level is determined based on review of safety and tolerability during Cycle 1 and enrollment for each schedule proceeds independently.
• Antitumor activity is assessed every 2 cycles.
• Whole blood is collected for PK assessment and peripheral blood mononuclear cells collected for PD assessment of the levels of phosphorylated 4E-BP1 , a downstream target of mTOR.
• Adverse events related to AP23573 during Cycle 1 in at least 2 patients include: mucositis, fatigue, rash, diarrhea, anorexia, and nausea. These events were mild or moderate in severity, reversible, and consistent with the toxicities of IV AP23573.
• Preliminary PK analysis indicates a median C max of 98.5 ng/mL (range 77-163) for the three schedules (20 mg/day, Day 1 of Cycle 1). Further PK analysis is ongoing. PD analysis demonstrates that phosphorylated 4E-BP1 levels are reduced by >80% 1 day after dosing and remain reduced during the dosing period, indicating potent and durable mTOR inhibition similar to that observed in with AP23573 IV. Antitumor activity was observed in two patients evaluated to date: a patient with metastatic breast carcinoma in the qdx4, 20 mg/day cohort (22% decrease), and a patient with metastatic renal cell carcinoma in the qdx21, 20mg/day cohort (21 % decrease). A third patient, with soft tissue sarcoma in the QDx4, 20 mg/day cohort has stable disease after 2 cycles.
• the mTOR inhibitor, AP23573 can be safely administered orally using several continuous and intermittent dosing schedules, achieves blood concentrations that portend activity with IV administration, potently inhibits mTOR, and has demonstrated early evidence of antitumor activity, with reported DLTs for patients on the QDx28 and QDx21 schedules, but no DLTs for patients on the QDx420 and 30mg/day schedule.
• Results These studies demonstrated evidence of anti-tumor activity as assessed by patients with Clinical Benefit Response (CBR). Seven patients of the 26 evaluable patients achieved a CBR. Six of them are sarcoma patients, including patients with osteosarcoma, leiomyosarcoma and other soft-tissue sarcomas. 43% of the thus far evaluable sarcoma patients were CBRs on these QDx5 schedules. The CBR patietns have been progression-free and receiving treatment from at least 4 months to 7 months to date.
• CBR Clinical Benefit Response
• the oral dose schedule of 40 mg QDx5 provided a good balance of potential therapeutic benefit against the risk of side-effects that were generally mild or moderate and manageable.
• the 40 mg QDx5 regimen every week provided a cumulative dose exposure of 800 mg AP23573 over 4 weeks, compared to the 4-week exposure level of 720 mg for a 30 mg QDx5 regimen ⁇ with a doubled day-1 dose each week), the 4-week exposure level of 315 mg for 15 mg QDx21 , and the 4-week exposure level of 280 mg for a daily dose of 10 mg (i.e., 10 mg QDx28).

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Oncology (AREA)
• Hematology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (2)

Family

ID=38049229

Family Applications (1)

Country Status (9)

Cited By (4)

Families Citing this family (19)

Family Cites Families (34)

• 2006
  • 2006-11-14 AU AU2006315512A patent/AU2006315512B2/en not_active Ceased
  • 2006-11-14 CN CN2006800510347A patent/CN101360495B/zh not_active Expired - Fee Related
  • 2006-11-14 JP JP2008540275A patent/JP5709354B2/ja not_active Expired - Fee Related
  • 2006-11-14 EA EA200801309A patent/EA015922B1/ru not_active IP Right Cessation
  • 2006-11-14 EP EP06844354A patent/EP1962839A4/en not_active Withdrawn
  • 2006-11-14 WO PCT/US2006/044146 patent/WO2007059106A2/en not_active Ceased
  • 2006-11-14 US US11/598,850 patent/US20070185150A1/en not_active Abandoned
  • 2006-11-14 CA CA002629714A patent/CA2629714A1/en not_active Abandoned
  • 2006-11-14 CN CN2012100014166A patent/CN102579467A/zh active Pending
  • 2006-11-14 EP EP13179744.1A patent/EP2662082A1/en not_active Withdrawn
• 2008
  • 2008-05-12 IL IL191356A patent/IL191356A0/en unknown
• 2013
  • 2013-09-13 JP JP2013191029A patent/JP2014012721A/ja active Pending

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events